1. Home
  2. IBRX vs WYNN Comparison

IBRX vs WYNN Comparison

Compare IBRX & WYNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

N/A

Current Price

$8.24

Market Cap

8.2B

Sector

Health Care

ML Signal

N/A

Logo Wynn Resorts Limited

WYNN

Wynn Resorts Limited

N/A

Current Price

$73.75

Market Cap

7.7B

ML Signal

N/A

Company Overview

Basic Information
Metric
IBRX
WYNN
Founded
2014
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Hotels/Resorts
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
8.2B
7.7B
IPO Year
2015
2002

Fundamental Metrics

Financial Performance
Metric
IBRX
WYNN
Price
$8.24
$73.75
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
21
Target Price
$14.25
★ $121.65
AVG Volume (30 Days)
★ 13.5M
2.0M
Earning Date
11-10-2026
11-05-2026
Dividend Yield
N/A
★ 1.35%
EPS Growth
★ 38.71
N/A
EPS
N/A
★ 2.36
Revenue
$113,288,000.00
★ $6,717,660,000.00
Revenue This Year
$99.98
$3.87
Revenue Next Year
$108.29
$3.21
P/E Ratio
★ N/A
$31.44
Revenue Growth
★ 668.31
10.67
52 Week Low
$1.95
$70.79
52 Week High
$12.43
$134.72

Technical Indicators

Market Signals
Indicator
IBRX
WYNN
Relative Strength Index (RSI) 43.83 40.24
Support Level $7.71 $73.07
Resistance Level $8.51 $77.89
Average True Range (ATR) 0.71 2.29
MACD -0.13 0.33
Stochastic Oscillator 18.18 40.28

Price Performance

Historical Comparison
IBRX
WYNN

About IBRX ImmunityBio Inc.

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

About WYNN Wynn Resorts Limited

Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, and Encore Boston Harbor in Massachusetts opened June 2019. We expect the company to continue to build nongaming rooms and attractions in Macao over the next few years, including a new 432-suite tower adjacent to its Palace resort opening in 2029. We model Wynn's managed integrated resort in the United Arab Emirates to open in 2027. The company received 49% and 51% of its 2025 prepandemic EBITDA from Macao and the US, respectively.

Share on Social Networks: